Literature DB >> 27125555

LN-1-255, a penicillanic acid sulfone able to inhibit the class D carbapenemase OXA-48.

Juan A Vallejo1, Marta Martínez-Guitián1, Juan C Vázquez-Ucha1, Concepción González-Bello2, Margarita Poza1, John D Buynak3, Christopher R Bethel4, Robert A Bonomo5, German Bou1, Alejandro Beceiro6.   

Abstract

OBJECTIVES: Carbapenemases are the most important mechanism responsible for carbapenem resistance in Enterobacteriaceae. Among carbapenemases, OXA-48 presents unique challenges as it is resistant to β-lactam inhibitors. Here, we test the capacity of the compound LN-1-255, a 6-alkylidene-2'-substituted penicillanic acid sulfone, to inhibit the activity of the carbapenemase OXA-48.
METHODS: The OXA-48 gene was cloned and expressed in Klebsiella pneumoniae and Escherichia coli in order to obtain MICs in the presence of inhibitors (clavulanic acid, tazobactam and sulbactam) and LN-1-255. OXA-48 was purified and steady-state kinetics was performed with LN-1-255 and tazobactam. The covalent binding mode of LN-1-255 with OXA-48 was studied by docking assays.
RESULTS: Both OXA-48-producing clinical and transformant strains displayed increased susceptibility to carbapenem antibiotics in the presence of 4 mg/L LN-1-255 (2-32-fold increased susceptibility) and 16 mg/L LN-1-255 (4-64-fold increased susceptibility). Kinetic assays demonstrated that LN-1-255 is able to inhibit OXA-48 with an acylation efficiency (k2/K) of 10 ± 1 × 10(4) M(-1) s(-1) and a slow deacylation rate (koff) of 7 ± 1 × 10(-4) s(-1). IC50 was 3 nM for LN-1-255 and 1.5 μM for tazobactam. Lastly, kcat/kinact was 500-fold lower for LN-1-255 than for tazobactam.
CONCLUSIONS: In these studies, carbapenem antibiotics used in combination with LN-1-255 are effective against the carbapenemase OXA-48, an important emerging mechanism of antibiotic resistance. This provides an incentive for further investigations to maximize the efficacy of penicillin sulfone inhibition of class D plasmid-carried Enterobacteriaceae carbapenemases.
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27125555      PMCID: PMC4954921          DOI: 10.1093/jac/dkw105

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  46 in total

Review 1.  Emerging carbapenemases: a global perspective.

Authors:  Timothy R Walsh
Journal:  Int J Antimicrob Agents       Date:  2010-11       Impact factor: 5.283

2.  Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.

Authors:  Krisztina M Papp-Wallace; Marisa L Winkler; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

Review 3.  Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes.

Authors:  Matthew E Falagas; Drosos E Karageorgopoulos; Patrice Nordmann
Journal:  Future Microbiol       Date:  2011-06       Impact factor: 3.165

4.  False extended-spectrum {beta}-lactamase phenotype in clinical isolates of Escherichia coli associated with increased expression of OXA-1 or TEM-1 penicillinases and loss of porins.

Authors:  Alejandro Beceiro; Sunil Maharjan; Tom Gaulton; Michel Doumith; Nelson C Soares; Hiran Dhanji; Marina Warner; Maeve Doyle; Mary Hickey; Gordon Downie; Germán Bou; David M Livermore; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2011-07-08       Impact factor: 5.790

5.  First outbreak of a plasmid-mediated carbapenem-hydrolyzing OXA-48 beta-lactamase in Klebsiella pneumoniae in Spain.

Authors:  Cristina Pitart; Mar Solé; Ignasi Roca; Anna Fàbrega; Jordi Vila; Francesc Marco
Journal:  Antimicrob Agents Chemother       Date:  2011-07-11       Impact factor: 5.191

Review 6.  OXA-48-like carbapenemases: the phantom menace.

Authors:  Laurent Poirel; Anaïs Potron; Patrice Nordmann
Journal:  J Antimicrob Chemother       Date:  2012-04-11       Impact factor: 5.790

7.  Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor.

Authors:  David E Ehmann; Haris Jahić; Philip L Ross; Rong-Fang Gu; Jun Hu; Gunther Kern; Grant K Walkup; Stewart L Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

8.  Strategic design of an effective beta-lactamase inhibitor: LN-1-255, a 6-alkylidene-2'-substituted penicillin sulfone.

Authors:  Priyaranjan Pattanaik; Christopher R Bethel; Andrea M Hujer; Kristine M Hujer; Anne M Distler; Magdalena Taracila; Vernon E Anderson; Thomas R Fritsche; Ronald N Jones; Sundar Ram Reddy Pagadala; Focco van den Akker; John D Buynak; Robert A Bonomo
Journal:  J Biol Chem       Date:  2008-10-27       Impact factor: 5.157

Review 9.  The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide.

Authors:  P Nordmann; L Poirel
Journal:  Clin Microbiol Infect       Date:  2014-09       Impact factor: 8.067

Review 10.  New β-lactamase inhibitors: a therapeutic renaissance in an MDR world.

Authors:  Sarah M Drawz; Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2013-12-30       Impact factor: 5.191

View more
  9 in total

1.  Activity of the β-Lactamase Inhibitor LN-1-255 against Carbapenem-Hydrolyzing Class D β-Lactamases from Acinetobacter baumannii.

Authors:  Juan Carlos Vázquez-Ucha; María Maneiro; Marta Martínez-Guitián; John Buynak; Christopher R Bethel; Robert A Bonomo; Germán Bou; Margarita Poza; Concepción González-Bello; Alejandro Beceiro
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 2.  New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections.

Authors:  Burcu Isler; Yohei Doi; Robert A Bonomo; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

3.  Discovery of Quercetin and Its Analogs as Potent OXA-48 Beta-Lactamase Inhibitors.

Authors:  Yuejuan Zhang; Cheng Chen; Bin Cheng; Lei Gao; Chuan Qin; Lixia Zhang; Xu Zhang; Jun Wang; Yi Wan
Journal:  Front Pharmacol       Date:  2022-06-22       Impact factor: 5.988

Review 4.  β-lactam/β-lactamase inhibitor combinations: an update.

Authors:  Kamaleddin H M E Tehrani; Nathaniel I Martin
Journal:  Medchemcomm       Date:  2018-08-17       Impact factor: 3.597

5.  Identifying Oxacillinase-48 Carbapenemase Inhibitors Using DNA-Encoded Chemical Libraries.

Authors:  Doris Mia Taylor; Justin Anglin; Suhyeorn Park; Melek N Ucisik; John C Faver; Nicholas Simmons; Zhuang Jin; Murugesan Palaniappan; Pranavanand Nyshadham; Feng Li; James Campbell; Liya Hu; Banumathi Sankaran; B V Venkataram Prasad; Hongbing Huang; Martin M Matzuk; Timothy Palzkill
Journal:  ACS Infect Dis       Date:  2020-03-25       Impact factor: 5.084

6.  Therapeutic Efficacy of LN-1-255 in Combination with Imipenem in Severe Infection Caused by Carbapenem-Resistant Acinetobacter baumannii.

Authors:  Juan Carlos Vázquez-Ucha; Marta Martínez-Guitián; María Maneiro; Concepción González-Bello; Margarita Poza; Alejandro Beceiro; Kelly Conde-Pérez; Laura Álvarez-Fraga; Gabriel Torrens; Antonio Oliver; John D Buynak; Robert A Bonomo; Germán Bou
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

Review 7.  Treatment of Infections by OXA-48-Producing Enterobacteriaceae.

Authors:  Adam Stewart; Patrick Harris; Andrew Henderson; David Paterson
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

Review 8.  New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams.

Authors:  Juan C Vázquez-Ucha; Jorge Arca-Suárez; Germán Bou; Alejandro Beceiro
Journal:  Int J Mol Sci       Date:  2020-12-06       Impact factor: 5.923

Review 9.  Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It.

Authors:  Zeinab Breijyeh; Buthaina Jubeh; Rafik Karaman
Journal:  Molecules       Date:  2020-03-16       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.